We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Ergot and non-ergot dopamine agonists and heart failure in patients with Parkinson's disease.
- Authors
Montastruc, François; Moulis, Florence; Araujo, Mélanie; Chebane, Leila; Rascol, Olivier; Montastruc, Jean-Louis
- Abstract
Purpose: Some studies have suggested a potential risk of heart failure in patients with Parkinson's disease receiving dopamine (DA) agonists. However, the results are conflicting. We used VigiBase®, the World Health Organization (WHO) Global Individual Case Safety Reports (ICSRs) database, to investigate a potential signal strengthening of heart failure with DA agonists in Parkinsonian patients older than 45 years. Methods: A case/non-case (disproportionality) analysis was performed in Vigibase® using ICSRs registered between 1978 and May 2016. The signal of disproportionality was calculated using reporting odds ratios (ROR). In our study, 154 ICSRs of heart failure occurring in 154 Parkinsonian patients (mean age 69.6 years, 51 % women) treated with DA agonists were included. Results and conclusion: There was a significant signal between occurrence of heart failure and exposure to pergolide or cabergoline in particular and ergot derivatives in general. In contrast, none signal was found for rotigotine, pramipexole, apomorphine, or ropinirole in particular and non-ergot derivatives in general. The present study underlines the importance to prescribe as DA agonists in Parkinsonian patients only non-ergot derivatives, excluding ergot drugs.
- Subjects
PARKINSON'S disease diagnosis; DOPAMINE agonists; ERGOT alkaloids; HEART failure; THERAPEUTICS
- Publication
European Journal of Clinical Pharmacology, 2017, Vol 73, Issue 1, p99
- ISSN
0031-6970
- Publication type
Article
- DOI
10.1007/s00228-016-2142-x